| The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe ZM Younossi, D Blissett, R Blissett, L Henry, M Stepanova, Y Younossi, ... Hepatology 64 (5), 1577-1586, 2016 | 1246 | 2016 |
| Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study E Vilar-Gomez, L Calzadilla-Bertot, VWS Wong, M Castellanos, ... Gastroenterology 155 (2), 443-457. e17, 2018 | 653 | 2018 |
| Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease BA Neuschwander‐Tetri, JM Clark, NM Bass, ML Van Natta, ... Hepatology 52 (3), 913-924, 2010 | 583 | 2010 |
| Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis R Loomba, M Abraham, A Unalp, L Wilson, J Lavine, E Doo, NM Bass, ... Hepatology 56 (3), 943-951, 2012 | 537 | 2012 |
| Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial R Aller, DA De Luis, O Izaola, R Conde, M Gonzalez Sagrado, D Primo, ... Eur Rev Med Pharmacol Sci 15 (9), 1090-5, 2011 | 462 | 2011 |
| Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites LT Evans, RW Kim, JJ Poterucha, PS Kamath Hepatology 37 (4), 897-901, 2003 | 395 | 2003 |
| The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile B Poirier, JP Bidouard, C Cadrouvele, X Marniquet, B Staels, SE O'connor, ... Diabetes, Obesity and Metabolism 7 (1), 65-72, 2005 | 294 | 2005 |
| The FTO Gene Is Associated With Adulthood Obesity in the Mexican Population M Villalobos‐Comparán, MT Flores‐Dorantes, MT Villarreal‐Molina, ... Obesity 16 (10), 2296-2301, 2008 | 185 | 2008 |
| Dietoterapia, nutrición clínica y metabolismo DDL Román, DB Guerrero, PPG Luna Ediciones Díaz de Santos, 2012 | 151 | 2012 |
| Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts R Mayo, J Crespo, I Martínez‐Arranz, JM Banales, M Arias, I Mincholé, ... Hepatology communications 2 (7), 807-820, 2018 | 141 | 2018 |
| Características nutricionales y estilo de vida en universitarios M Ledo-Varela, DA de Luis Román, M González-Sagrado, ... Nutrición Hospitalaria 26 (4), 814-818, 2011 | 135 | 2011 |
| Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. R Aller, O Izaola, S Gómez, C Tafur, G González, E Berroa, N Mora, ... European Review for Medical & Pharmacological Sciences 19 (16), 2015 | 129 | 2015 |
| Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease R Younes, GP Caviglia, O Govaere, C Rosso, A Armandi, T Sanavia, ... Journal of hepatology 75 (4), 786-794, 2021 | 120 | 2021 |
| Leptin receptor polymorphisms interact with polyunsaturated fatty acids to augment risk of insulin resistance and metabolic syndrome in adults CM Phillips, L Goumidi, S Bertrais, MR Field, JM Ordovas, LA Cupples, ... The Journal of nutrition 140 (2), 238-244, 2010 | 117 | 2010 |
| Diagnosis of Hepatopulmonary Syndrome with Contrast Transesophageal Echocardiography (Advantages over Contrast Transthoracic Echocardiography) R Aller, JL Moya, V Moreira, D Boixeda, A Cano, J Picher, S Garcia-Rull, ... Digestive diseases and sciences 44, 1243-1248, 1999 | 114 | 1999 |
| Bioelectrical impedance and strength measurements in patients with heart failure: comparison with functional class LC Martínez, EC Ramírez, AO Tejeda, EA Lafuente, LPB Rosales, ... Nutrition 23 (5), 412-418, 2007 | 104 | 2007 |
| Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline R Aller, C Fernandez-Rodriguez, O Lo Iacono, R Banares, J Abad, ... Gastroenterología y Hepatología (English Edition) 41 (5), 328-349, 2018 | 102 | 2018 |
| Mediterranean diet is associated with liver histology in patients with non alcoholic fatty liver disease R Aller, O Izaola, B de la Fuente, D de Luis Nutricion hospitalaria 32 (6), 2518-2524, 2015 | 79 | 2015 |
| Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin MA Jimenez-Sousa, R Almansa, C de la Fuente, A Caro-Paton, L Ruiz, ... European Cytokine Network 21 (2), 84-91, 2010 | 63 | 2010 |
| Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin MA Jimenez-Sousa, R Almansa, C de la Fuente, A Caro-Paton, L Ruiz, ... European Cytokine Network 21 (2), 84-91, 2010 | 63 | 2010 |
Daniel De LuisProfessor Endocrinolgy and NutritionVerified email at uva.es
